Esther Abels has a background in bridging R&D, proof of concept, socio economics and pivotal clinical validation studies used for registration purposes in different geographies, for both pharma and biotech products. She has a wealth of regulatory and clinical experience specializing in bringing products to clinical utility. She played a crucial role in getting Whole Slide Imaging devices reclassified in USA.
Esther drives efforts for reimbursement in Digital Pathology and collaborations with different Pathology Associations. In 2022 she was the president for the Digital Pathology Association (DPA) and she has chaired the DPA Regulatory and Standards Taskforce and facilitates FDA collaborations to drive regulatory and standard clarifications for interoperability and computational pathology in the field of digital pathology.
She is also a co-founder of the Alliance for Digital Pathology / Pathology Innovation Collaborative Community where she co-leads the reimbursement workgroup.
Esther holds a MSc in Biomedical Health Science from Radboud University Nijmegen.